Published on February 20, 2014 at 11:42 PM
BDI Pharma today announced the launch of The MERREM Commitment Program™ with AstraZeneca, an assurance initiative offering customers security in product availability through contracted access to the original, branded MERREM®I.V. from AstraZeneca. Along with this innovative new partnership, BDI Pharma was awarded the status of Authorized Distributor of Record (ADR) for AstraZeneca and is the sole and exclusive distributor of contracted MERREM®I.V. in the United States.
"We are excited about this new program and what it means to the healthcare community," stated Anthony Jackson, COO for BDI Pharma. "We are all aware that drug shortages can be costly, unpredictable, and potentially threaten patients' treatment. With The MERREM Commitment Program™, our customers will have peace of mind that their institution has access to product now, and through potential shortages of generic meropenem."
SOURCE BDI Pharma, Inc.